Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:4186'
s PB Ratio Range Over the Past 10 Years
Min: 2.85 Med: 6.48 Max: 16.43
Current: 2.9
During the past 13 years, Taiwan Advance Bio-Pharmaceutical's highest PB Ratio was 16.43. The lowest was 2.85. And the median was 6.48.
ROCO:4186's PB Ratio is ranked worse than 51.18% of 1227
companies
in the Biotechnology industry
Industry Median: 2.75
vs ROCO:4186: 2.90
During the past 12 months, Taiwan Advance Bio-Pharmaceutical's average Book Value Per Share Growth Rate was 11.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 5.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -2.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -1.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Taiwan Advance Bio-Pharmaceutical was 22.40% per year. The lowest was -26.90% per year. And the median was -4.10% per year.
Back to Basics: PB Ratio
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Taiwan Advance Bio-Pharmaceutical PB Ratio Related Terms
Taiwan Advance Bio-Pharmaceutical PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4186 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Taiwan Advance Bio-Pharmaceutical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiwan Advance Bio-Pharmaceutical PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Taiwan Advance Bio-Pharmaceutical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Taiwan Advance Bio-Pharmaceutical's PB Ratio falls into.
Taiwan Advance Bio-Pharmaceutical PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Taiwan Advance Bio-Pharmaceutical (ROCO:4186) has a PB Ratio of 2.89 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. This is 55% below median its historical median of 6.48. Over the past decade, Taiwan Advance Bio-Pharmaceutical's PB Ratio has ranged from 2.85 to 16.43. According to the industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #628 out of 1227 companies in the Biotechnology industry, placing it in the top 51.2%.
Is Taiwan Advance Bio-Pharmaceutical's PB Ratio too high?
Taiwan Advance Bio-Pharmaceutical's current PB Ratio of 2.89 is 55% below median its 10-year median of 6.48. Over the past 10 years, this metric has ranged from a low of 2.85 to a high of 16.43. The Biotechnology industry median PB Ratio is 2.75. Taiwan Advance Bio-Pharmaceutical's value of 2.89 is 5.1% above this industry median. Based on the distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #628 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Taiwan Advance Bio-Pharmaceutical has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Taiwan Advance Bio-Pharmaceutical's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Advance Bio-Pharmaceutical ranks #628 out of 1227 companies for PB Ratio. This places Taiwan Advance Bio-Pharmaceutical in the lower half of its industry. The industry median PB Ratio is 2.75. Taiwan Advance Bio-Pharmaceutical's value of 2.89 is 5.1% above this benchmark. Historically, Taiwan Advance Bio-Pharmaceutical's own PB Ratio has ranged from 2.85 to 16.43 over the past decade. While the company's 10-year median is 6.48 vs. the industry median of 2.75, Taiwan Advance Bio-Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.75, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiwan Advance Bio-Pharmaceutical's current PB Ratio of 2.89 is 5.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Taiwan Advance Bio-Pharmaceutical and its competitors. For the Biotechnology industry, the median PB Ratio is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Advance Bio-Pharmaceutical's current PB Ratio is 2.89, which is 55% below median its own 10-year median of 6.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Advance Bio-Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical (ROCO:4186) is currently considered Possible Value Trap. The stock's GF Value™ is NT$17.94, compared to a current price of NT$9.15 — trading 49% below its estimated fair value. The current PB Ratio is 2.89, which is 55% below median its 10-year median of 6.48 and 5.1% above the Biotechnology industry median of 2.75. Taiwan Advance Bio-Pharmaceutical's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Taiwan Advance Bio-Pharmaceutical (ROCO:4186), the current PB Ratio is 2.89 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Advance Bio-Pharmaceutical (ROCO:4186) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Advance Bio-Pharmaceutical stock appears to be undervalued.
The current stock price of NT$9.15 is trading 49% below its estimated GF Value™ of NT$17.94.
GuruFocus considers Taiwan Advance Bio-Pharmaceutical to be Possible Value Trap.
Key valuation signals for ROCO:4186:
PB Ratio: 2.89 (55% below median its 10-year median of 6.48)
GF Value™: NT$17.94 vs. price of NT$9.15 (49% below fair value)
Industry Position: 5.1% above the Biotechnology median (#628 of 1227)
No single metric tells the full story. See the ROCO:4186 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Advance Bio-Pharmaceutical Business Description
Taiwan Advance Bio-Pharmaceutical Inc operates in the food safety industry. The company's products include a Food safety test kit, Animal test kit, Pesticide test kit, Mycotoxin test kit, Nuleic acid extraction kit.
51GF Score
Get the complete analysis for ROCO:4186
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4186 has been successfully added to your 
